Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KRAS mutant inhibitor ALTA3263

An orally bioavailable non-covalent dual ON/OFF state inhibitor of multiple oncogenic KRAS mutant forms, including KRAS G12V, G12D and G12C, with potential antineoplastic activity. Upon oral administration, KRAS mutant inhibitor ALTA3263 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:KRAS inhibitor ALTA3263
KRAS isoform-selective inhibitor ALTA3263
Code name:ALTA 3263
ALTA-3263
ALTA3263
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search